HR 806

To amend the Federal Food, Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs.

Congress: 110 (2007–2009, Ended)
Chamber: House
Policy Area: Health
Introduced: Feb 5, 2007
Current Status: Referred to the House Committee on Energy and Commerce.
Latest Action: Referred to the House Committee on Energy and Commerce. (Feb 5, 2007)
Official Text: https://www.congress.gov/bill/110th-congress/house-bill/806

Sponsor

Name: Rep. Emerson, Jo Ann [R-MO-8]
Party: Republican • **State:** MO • **Chamber:** House

Cosponsors (6 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Berry, Marion [D-AR-1]	D · AR		Feb 5, 2007
Rep. Moore, Dennis [D-KS-3]	D · KS		Feb 5, 2007
Rep. Wamp, Zach [R-TN-3]	R · TN		Feb 5, 2007
Rep. Mollohan, Alan B. [D-WV-1]	D · WV		Feb 16, 2007
Rep. Holden, Tim [D-PA-17]	D · PA		Mar 7, 2007
Rep. Rahall, Nick J., II [D-WV-3]	D · WV		Apr 17, 2007

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred To	Feb 5, 2007

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
110 S 438	Related bill	**Jan 30, 2007:** Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (text of measure as introduced: CR S1352)

Summary (as of Feb 5, 2007)

Amends the Federal Food, Drug, and Cosmetic Act to prohibit a holder of a new, approved drug application from commencing to manufacture, market, sell, or distribute a generic version of such drug from the time of the receipt of notice from the generic manufacturer that an abbreviated new drug application has been submitted for approval until the expiration or forfeiture of the exclusivity period granted to the generic manufacturer.

Actions Timeline

- **Feb 5, 2007:** Introduced in House
- **Feb 5, 2007:** Referred to the House Committee on Energy and Commerce.